A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

• Main Authors: Roland Kratzer (Author), Benoît Sansas (Author), Karine Lélu (Author), Alexei Evlachev (Author), Doris Schmitt (Author), Nathalie Silvestre (Author), Geneviève Inchauspé (Author), Perrine Martin (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pre-clinical models mimicking persistent hepatitis B virus (HBV) expression are seldom, do not capture all features of a human chronic infection and due to their complexity, are subject to variability. We report a meta-analysis of seven experiments performed with TG1050, an HBV-targeted immunotherap...